The administration of BDNF and GDNF to the brain via PLGA microparticles patterned within a degradable PEG‐based hydrogel: Protein distribution and the glial response
Source abstract
Abstract
Abstract Tailored delivery of neurotrophic factors (NFs) is a critical challenge that continues to inhibit strategies for guidance of axonal growthin vivo. Of particular importance is the ability to recreate innervation of distant brain regions by transplant tissue, for instance rebuilding the nigrostriatal track, one focus in Parkinson's disease research. Many strategies have utilized polymer drug delivery to target NF release in space and time, but combinatorial approaches are needed to deliver multiple NFs at relevant therapeutic times and locations without toxic side effects. Here we engineered a paradigm of PLGA microparticles entrapped within a degradable PEG‐based hydrogel device to locally release two different types of NFs with two different release profiles. Hydrogel/microparticle devices were developed and analyzed for their ability to release GDNF in the caudal area of the brain, near the substantia nigra, or BDNF in the rostral area, near the striatum. The devices delivered their respective NFs in a region localized to within 100 μm of the bridge, but not exclusively to the targeted rostral or caudal ends. BDNF was slowly released over a 56‐day period, whereas a bolus of GDNF was released around 28 days. The timed delivery of NFs from implanted devices significantly reduced the microglial response relative to sham surgeries. Given the coordinated drug delivery ability and reduced localized inflammatory response, this multifaceted PEG hydrogel/PLGA microparticle strategy may be a useful tool for further development in combining tissue engineering and drug delivery, and recreating the nigrostriatal track. © 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part A, 2011.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nerve injury and regeneration · Neuroscience and Neural Engineering · Neurogenesis and neuroplasticity mechanisms
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (66)
Show source-provided references
1. 10.1016/j.addr.2007.03.01410.1016/j.addr.2007.03.014 ↗
2. 10.1023/A:101191191217410.1023/A:1011911912174 ↗
3. 10.1073/pnas.91.12.570510.1073/pnas.91.12.5705 ↗
4. 10.1146/annurev.neuro.24.1.67710.1146/annurev.neuro.24.1.677 ↗
5. 10.1016/S0165-0173(00)00030-810.1016/S0165-0173(00)00030-8 ↗
6. 10.1172/JCI2917810.1172/JCI29178 ↗
7. 10.1038/nrd208710.1038/nrd2087 ↗
8. 10.1002/jnr.2205410.1002/jnr.22054 ↗
9. 10.1006/mcne.1998.068410.1006/mcne.1998.0684 ↗
10. 10.1523/JNEUROSCI.21-17-06706.200110.1523/JNEUROSCI.21-17-06706.2001 ↗
11. 10.1523/JNEUROSCI.21-17-06718.200110.1523/JNEUROSCI.21-17-06718.2001 ↗
12. 10.1126/science.105958110.1126/science.1059581 ↗
13. 10.1016/S0301-0082(00)00014-910.1016/S0301-0082(00)00014-9 ↗
14. 10.1097/00005072-199907000-0000710.1097/00005072-199907000-00007 ↗
15. 10.1016/0896-6273(91)90273-310.1016/0896-6273(91)90273-3 ↗
16. 10.1080/0897719041000172330810.1080/08977190410001723308 ↗
17. 10.1006/exnr.1996.020310.1006/exnr.1996.0203 ↗
18. 10.1006/exnr.1996.001110.1006/exnr.1996.0011 ↗
19. 10.1016/j.brainres.2004.12.05410.1016/j.brainres.2004.12.054 ↗
20. 10.1126/science.849355710.1126/science.8493557 ↗
21. 10.1016/0006-8993(96)00345-910.1016/0006-8993(96)00345-9 ↗
22. 10.1002/j.1460-2075.1995.tb07052.x10.1002/j.1460-2075.1995.tb07052.x ↗
23. 10.1016/0306-4522(96)00343-010.1016/0306-4522(96)00343-0 ↗
24. 10.1038/nm85010.1038/nm850 ↗
25. 10.1016/j.biomaterials.2006.12.02110.1016/j.biomaterials.2006.12.021 ↗
26. 10.1016/j.ijpharm.2005.09.04010.1016/j.ijpharm.2005.09.040 ↗
27. 10.3171/jns.2001.95.3.048910.3171/jns.2001.95.3.0489 ↗
28. 10.1016/S0142-9612(03)00601-X10.1016/S0142-9612(03)00601-X ↗
29. 10.1016/j.jconrel.2008.12.01010.1016/j.jconrel.2008.12.010 ↗
30. 10.1523/JNEUROSCI.4421-04.200510.1523/JNEUROSCI.4421-04.2005 ↗
31. Nicholls JG · 2001
32. 10.1016/S0006-8993(97)01408-X10.1016/S0006-8993(97)01408-X ↗
33. 10.1002/cne.2202810.1002/cne.22028 ↗
34. 10.1006/exnr.1996.014110.1006/exnr.1996.0141 ↗
35. 10.1177/10738580223770310.1177/107385802237703 ↗
36. GDNF‐enhanced collagen bridges increase neuritic outgrowth to striatum from VM transplants
37. 10.1177/09636897990080011410.1177/096368979900800114 ↗
38. 10.1016/j.jconrel.2007.02.00510.1016/j.jconrel.2007.02.005 ↗
39. 10.1016/S0169-409X(97)00048-310.1016/S0169-409X(97)00048-3 ↗
40. 10.1002/jbm.a.3280910.1002/jbm.a.32809 ↗
41. 10.3727/09636890878442329210.3727/096368908784423292 ↗
42. 10.1016/j.ejpb.2005.11.00610.1016/j.ejpb.2005.11.006 ↗
43. 10.1016/j.neulet.2003.11.05110.1016/j.neulet.2003.11.051 ↗
44. 10.1016/j.jconrel.2003.12.01210.1016/j.jconrel.2003.12.012 ↗
45. 10.1016/S0168-3659(01)00500-410.1016/S0168-3659(01)00500-4 ↗
46. 10.1016/j.biomaterials.2005.11.00710.1016/j.biomaterials.2005.11.007 ↗
47. 10.1016/j.actbio.2009.01.03610.1016/j.actbio.2009.01.036 ↗
48. Effect of macromer weight percent on neural cell growth in 2D and 3D nondegradable PEG hydrogel culture10.1002/jbm.a.32787 ↗
49. 10.1017/S1740925X0700048810.1017/S1740925X07000488 ↗
50. 10.1021/ma00056a00510.1021/ma00056a005 ↗
51. 10.1006/exnr.2000.741710.1006/exnr.2000.7417 ↗
52. 10.1038/350230a010.1038/350230a0 ↗
53. Paxinos G · 2007
54. Biocompatibility and drug release of poly(ethylene) glycol (peg)‐based hydrogel in healthy rat brain tissue
55. 10.1021/ma010025y10.1021/ma010025y ↗
56. 10.1016/j.biomaterials.2005.06.03410.1016/j.biomaterials.2005.06.034 ↗
57. 10.1021/js960160210.1021/js9601602 ↗
58. 10.1093/brain/awl16510.1093/brain/awl165 ↗
59. 10.1002/glia.110610.1002/glia.1106 ↗
60. 10.1111/j.1460-9568.1994.tb00981.x10.1111/j.1460-9568.1994.tb00981.x ↗
61. 10.1039/b923544b10.1039/b923544b ↗
62. 10.1002/bit.2235210.1002/bit.22352 ↗
63. 10.1089/ten.tea.2009.050910.1089/ten.tea.2009.0509 ↗
64. 10.1073/pnas.070409110410.1073/pnas.0704091104 ↗
65. 10.1038/nrd74410.1038/nrd744 ↗
66. 10.1046/j.1460-9568.2003.02456.x10.1046/j.1460-9568.2003.02456.x ↗